Your browser is no longer supported. Please, upgrade your browser.
Settings
CHNA Loncar China BioPharma ETF daily Stock Chart
CHNA [NASD]
Loncar China BioPharma ETF
Index- P/E- EPS (ttm)- Insider Own- Shs Outstand- Perf Week4.39%
Market Cap- Forward P/E- EPS next Y- Insider Trans- Shs Float- Perf Month1.46%
Income- PEG- EPS next Q- Inst Own- Short Float- Perf Quarter27.62%
Sales- P/S- EPS this Y- Inst Trans- Short Ratio- Perf Half Y27.01%
Book/sh- P/B- EPS next Y- ROA- Target Price- Perf Year56.46%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range19.00 - 34.50 Perf YTD32.73%
Dividend0.04 P/FCF- EPS past 5Y- ROI- 52W High-6.17% Beta-
Dividend %0.12% Quick Ratio- Sales past 5Y- Gross Margin- 52W Low70.37% ATR0.75
Employees- Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)54.71 Volatility1.21% 1.83%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.69 Prev Close32.91
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume5.49K Price32.37
Recom- SMA20-0.01% SMA505.44% SMA20023.55% Volume1,508 Change-1.65%
Mar-18-20 08:45AM  
Feb-13-20 08:44AM  
Aug-15-19 08:00AM  
Jun-05-19 03:11PM  
Jun-03-19 02:46PM  
Apr-10-19 01:00PM  
Nov-30-18 08:00AM  
Aug-19-18 11:20AM  
Aug-16-18 12:25PM  
Aug-15-18 09:50PM  
02:00PM  
The investment seeks to track the performance, before fees and expenses, of the Loncar China BioPharma Index (the index). Under normal circumstances, at least 80% of the fund's total assets (exclusive of any collateral held from securities lending) will be invested in the component securities of the index or in depositary receipts representing such component securities. The index seeks to track the performance of a modified equal-weighted portfolio of companies directly involved in the growth of China's pharmaceutical and biotech related industries. The fund is non-diversified.